Corcept Therapeutics (CORT) — insider trading
Health Care
Corcept Therapeutics (CORT) has 43 reported SEC Form 4 insider transactions in our data, including 16 open-market sales among the most recent 43 (latest 2026-07-07).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-07 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion (derivative) | 20,000 | $0.00 | $0 | Form 4 |
| 2026-07-07 | Guyer William | Officer (Chief Development Officer) | Open-market sale | 952 | $93.54 | $89.0K | Form 4 |
| 2026-07-07 | Guyer William | Officer (Chief Development Officer) | Open-market sale | 19,048 | $93.11 | $1.77M | Form 4 |
| 2026-07-07 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion | 20,000 | $21.65 | $433.0K | Form 4 |
| 2026-07-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 25,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 11,175 | $89.31 | $998.0K | Form 4 |
| 2026-07-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 2,801 | $88.51 | $247.9K | Form 4 |
| 2026-07-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 11,024 | $87.33 | $962.8K | Form 4 |
| 2026-07-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 25,000 | $8.27 | $206.8K | Form 4 |
| 2026-06-17 | MAHONEY DAVID L | Director | Open-market sale | 20,000 | $84.53 | $1.69M | Form 4 |
| 2026-06-16 | WILSON JAMES N | Director | Open-market sale | 5,823 | $83.57 | $486.6K | Form 4 |
| 2026-06-16 | WILSON JAMES N | Director | Open-market sale | 4,177 | $82.69 | $345.4K | Form 4 |
| 2026-06-15 | Mokari Atabak | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Mokari Atabak | Officer (Chief Financial Officer) | Open-market sale | 2 | $82.45 | $165 | Form 4 |
| 2026-06-15 | Mokari Atabak | Officer (Chief Financial Officer) | Open-market sale | 19,483 | $81.81 | $1.59M | Form 4 |
| 2026-06-15 | Mokari Atabak | Officer (Chief Financial Officer) | Open-market sale | 11,081 | $80.94 | $896.9K | Form 4 |
| 2026-06-15 | Mokari Atabak | Officer (Chief Financial Officer) | Open-market sale | 9,434 | $80.02 | $754.9K | Form 4 |
| 2026-06-15 | Mokari Atabak | Officer (Chief Financial Officer) | Option exercise / conversion | 40,000 | $19.26 | $770.4K | Form 4 |
| 2026-06-02 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion (derivative) | 20,000 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Guyer William | Officer (Chief Development Officer) | Open-market sale | 20,000 | $70.60 | $1.41M | Form 4 |
| 2026-06-02 | Guyer William | Officer (Chief Development Officer) | Option exercise / conversion | 20,000 | $21.65 | $433.0K | Form 4 |
| 2026-06-02 | Robb Gary Charles | Officer (Chief Business Officer) | Shares withheld for taxes / exercise cost | 358 | $70.44 | $25.2K | Form 4 |
| 2026-06-02 | Mokari Atabak | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 395 | $70.44 | $27.8K | Form 4 |
| 2026-06-02 | Maduck Sean | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 452 | $70.44 | $31.8K | Form 4 |
| 2026-06-02 | Lyon Joseph Douglas | Officer (See Remarks) | Shares withheld for taxes / exercise cost | 269 | $70.44 | $18.9K | Form 4 |
| 2026-06-01 | Robb Gary Charles | Officer (Chief Business Officer) | Grant / award / vesting | 776 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Robb Gary Charles | Officer (Chief Business Officer) | Grant / award / vesting | 776 | $70.44 | $54.7K | Form 4 |
| 2026-06-01 | Mokari Atabak | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 40,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Mokari Atabak | Officer (Chief Financial Officer) | Grant / award / vesting | 634 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Mokari Atabak | Officer (Chief Financial Officer) | Grant / award / vesting | 634 | $70.44 | $44.7K | Form 4 |
| 2026-06-01 | Mokari Atabak | Officer (Chief Financial Officer) | Open-market sale | 40,000 | $70.00 | $2.80M | Form 4 |
| 2026-06-01 | Mokari Atabak | Officer (Chief Financial Officer) | Option exercise / conversion | 40,000 | $19.26 | $770.4K | Form 4 |
| 2026-06-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion (derivative) | 25,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Maduck Sean | Officer (See Remarks) | Grant / award / vesting | 615 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Maduck Sean | Officer (See Remarks) | Grant / award / vesting | 615 | $70.44 | $43.3K | Form 4 |
| 2026-06-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 3,931 | $70.75 | $278.1K | Form 4 |
| 2026-06-01 | Maduck Sean | Officer (See Remarks) | Open-market sale | 21,069 | $70.11 | $1.48M | Form 4 |
| 2026-06-01 | Maduck Sean | Officer (See Remarks) | Option exercise / conversion | 25,000 | $8.27 | $206.8K | Form 4 |
| 2026-06-01 | Guyer William | Officer (Chief Development Officer) | Grant / award / vesting | 877 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Guyer William | Officer (Chief Development Officer) | Grant / award / vesting | 877 | $70.44 | $61.8K | Form 4 |
| 2026-06-01 | Lyon Joseph Douglas | Officer (See Remarks) | Grant / award / vesting | 537 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Lyon Joseph Douglas | Officer (See Remarks) | Grant / award / vesting | 537 | $70.44 | $37.8K | Form 4 |
| 2026-05-27 | Robb Gary Charles | Officer (Chief Business Officer) | Bona fide gift | 600 | $0.00 | $0 | Form 4 |
Ask the chat about CORT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Corcept Therapeutics (CORT).
Last updated 2026-07-07 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.